351 related articles for article (PubMed ID: 17123798)
1. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
Ambrogi V; Perioli L; Marmottini F; Rossi C
Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
[TBL] [Abstract][Full Text] [Related]
2. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
3. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Zahedi P; Lee PI
Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.
Remenar JF; Peterson ML; Stephens PW; Zhang Z; Zimenkov Y; Hickey MB
Mol Pharm; 2007; 4(3):386-400. PubMed ID: 17497886
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.
Albers J; Alles R; Matthée K; Knop K; Nahrup JS; Kleinebudde P
Eur J Pharm Biopharm; 2009 Feb; 71(2):387-94. PubMed ID: 18951978
[TBL] [Abstract][Full Text] [Related]
6. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib.
Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
J Pharm Pharmacol; 2005 Oct; 57(10):1271-8. PubMed ID: 16259755
[TBL] [Abstract][Full Text] [Related]
7. Molecular interactions in celecoxib-PVP-meglumine amorphous system.
Gupta P; Bansal AK
J Pharm Pharmacol; 2005 Mar; 57(3):303-10. PubMed ID: 15807985
[TBL] [Abstract][Full Text] [Related]
8. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.
Bozdağ-Pehlivan S; Subaşi B; Vural I; Unlü N; Capan Y
Acta Pol Pharm; 2011; 68(3):423-33. PubMed ID: 21648198
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
[TBL] [Abstract][Full Text] [Related]
11. Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying.
Bohr A; Kristensen J; Stride E; Dyas M; Edirisinghe M
Int J Pharm; 2011 Jun; 412(1-2):59-67. PubMed ID: 21511018
[TBL] [Abstract][Full Text] [Related]
12. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
[TBL] [Abstract][Full Text] [Related]
13. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
14. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
16. Modification of the crystal habit of celecoxib for improved processability.
Banga S; Chawla G; Varandani D; Mehta BR; Bansal AK
J Pharm Pharmacol; 2007 Jan; 59(1):29-39. PubMed ID: 17227618
[TBL] [Abstract][Full Text] [Related]
17. Formation of celecoxib nanoparticles from volatile microemulsions.
Margulis-Goshen K; Kesselman E; Danino D; Magdassi S
Int J Pharm; 2010 Jun; 393(1-2):230-7. PubMed ID: 20403417
[TBL] [Abstract][Full Text] [Related]
18. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.
Kushida I; Gotoda M
Drug Dev Ind Pharm; 2013 Oct; 39(10):1582-8. PubMed ID: 22519663
[TBL] [Abstract][Full Text] [Related]
19. The use of spray-drying to enhance celecoxib solubility.
Fouad EA; El-Badry M; Mahrous GM; Alanazi FK; Neau SH; Alsarra IA
Drug Dev Ind Pharm; 2011 Dec; 37(12):1463-72. PubMed ID: 21707230
[TBL] [Abstract][Full Text] [Related]
20. Devitrification of amorphous celecoxib.
Gupta P; Bansal AK
AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
